Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 388; číslo 23; s. 2159 - 2170
Hlavní autori:	Eskander, Ramez N., Sill, Michael W., Beffa, Lindsey, Moore, Richard G., Hope, Joanie M., Musa, Fernanda B., Mannel, Robert, Shahin, Mark S., Cantuaria, Guilherme H., Girda, Eugenia, Mathews, Cara, Kavecansky, Juraj, Leath, Charles A., Gien, Lilian T., Hinchcliff, Emily M., Lele, Shashikant B., Landrum, Lisa M., Backes, Floor, O’Cearbhaill, Roisin E., Al Baghdadi, Tareq, Hill, Emily K., Thaker, Premal H., John, Veena S., Welch, Stephen, Fader, Amanda N., Powell, Matthew A., Aghajanian, Carol
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 08.06.2023
Predmet:	Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Cancer therapies Carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Chemotherapy Cytotoxicity DNA Mismatch Repair Double-Blind Method Endometrial cancer Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Endometrium Female Gynecologic Oncology Gynecology Hematology Humans Hypotheses Immunotherapy Laboratories Mismatch repair Monoclonal antibodies Obstetrics Oncology Paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects Pembrolizumab Placebos Statistical analysis Survival Targeted cancer therapy Treatments in Oncology Tumors Japan
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!